NOVOLIN N (human insulin) by Novo Nordisk. Approved for insulin [epc]. First approved in 1991.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
NOVOLIN N is a human insulin product approved by the FDA in 1991, manufactured by Novo Nordisk. It is an intermediate-acting insulin used to treat diabetes mellitus by regulating blood glucose levels. The product works through the insulin pharmacologic class mechanism to improve glycemic control in both type 1 and type 2 diabetes patients. It is administered via subcutaneous injection and represents a foundational insulin therapy option in the treatment landscape.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Worked on NOVOLIN N at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNOVOLIN N creates roles for brand managers focused on mature product lifecycle management, field sales representatives engaging primary care and endocrinology practices, and account managers servicing pharmacy benefits and health plans. Professionals supporting this product require expertise in diabetes care, payer negotiations, generic transition planning, and healthcare economics as the product approaches loss of exclusivity. Currently, zero open positions are linked to this product in the dataset, reflecting its mature market stage and diminishing commercial growth opportunities.